Collaborating to Advance Our Programs and Technologies

At AVI BioPharma we are committed to rapidly advancing our leading RNA-based technology platforms and pipeline. Strategically, we seek to build a diversified research and development portfolio balanced between select programs partnered with larger biopharmaceutical companies and AVI retained programs.

Platform Opportunities
Our RNA-based technologies and PMO-X™, PMOplus™ and PPMO chemistries combine to make a versatile, collaboration-ready, therapeutics research and development platform with broad applicability. Our platform has demonstrated utility across multiple therapeutic categories, including the promise of potentially transformative, safe and effective treatment options for rare and infectious diseases.

Program Opportunities
In addition to offering our collaboration-ready RNA-based technology platform, we have multiple program opportunities available for partnering, including our clinical stage Duchenne muscular dystrophy program and several anti-infective and rare disease programs.

Beyond strategic partnerships with industry, AVI also maintains a continuing interest in establishing research-advancing collaborative agreements with select academic, governmental and non-governmental organizations.

For further information on partnering and collaboration with AVI, please send an email to AVI at partnering@avibio.com.

This page was last updated on June 27, 2011.